Find an Article

Filter articles

Applied Filters

Showing 31 to 40 of 51 results

Stem cells in Costa Rica: a boost for medical research

Costa Rica04-07-2017

Now that Costa Rica has allowed adult stem cells to be used as part of regenerative therapies, the country should be able to attract more investment, say María del Pilar López and Esteban Monge of Zürcher Lawyers.

Navigating medical use in Japan


A handful of high-profile disputes over medical use patents have been decided in Japan, as Osamu Yamamoto of Yuasa and Hara reports.

Life sciences regulation in India: the need for evolution

India15-06-2017Kirit Javali

India’s regulatory environment surrounding pharmaceuticals and medical devices needs to evolve in order to unlock the industries’ true potential, says Kirit Javali of Jafa & Javali.

Medical devices new rules: the clock is ticking

EU13-06-2017Jo Emmett

A new EU regulation on implantable medical devices takes steps to acknowledge that patient outcomes and safety are primary goals, but the transition to the new system might not be easy for industry stakeholders, says Jo Emmett of Premier Research.

Patent eligibility for healthcare IT applications

US23-02-2017Stacy Taylor

As securing patent eligibility for ‘healthcare IT’ applications seems to be becoming easier, companies looking to monetise IP in this area can breathe a sigh of relief. Stacy Taylor of DLA Piper explains more.

New technologies, old framework: maximising IP protection for 3D printing in the life sciences

US05-01-2017Arlene Chow and Nitya Anand

IP law has yet to catch up with the technological capabilities of 3D printing, but by taking pre-emptive action, companies can maximise their IP protection under the current legal framework. Arlene Chow and Nitya Anand of Hogan Lovells report.

Event preview: Life Sciences Patents Network Europe 2016


On December 7, LSIPR will be hosting the Life Sciences Patents Network Europe 2016 at the Bloomsbury Hotel in London. Here we preview the main talking points.

Mind your language

Germany20-09-2016Bernd Allekotte and Markus Grammel

A decision by Germany’s Federal Court of Justice has developed the concept of the ‘doctrine of equivalents’, possibly benefiting pharma patent owners, say Bernd Allekotte and Markus Grammel of Grünecker.

Preview: Life Sciences IP Summit 2016

EU16-09-2016Sarah Porch

Ahead of the Life Sciences IP Summit 2016 from October 20 to 21 at the Hilton London Paddington Hotel, Sarah Porch of C5 previews the main talking points, including Brexit and the UPC.

IP in the digital age: a tricky path ahead for pharma companies?

EU13-09-2016Stephen Bennett, Elisabethann Wright, Mark Marfe and James Cross

The pharmaceutical industry needs to adjust its expectations of the scope of IP protection available in the digital age, say Stephen Bennett, Elisabethann Wright and Mark Marfe of Hogan Lovells, and James Cross of RGC Jenkins.

Showing 31 to 40 of 51 results